Frederik E. Stuurman
- Oncology
- Pharmaceutical Science top 5%
- Molecular Biology
- Pulmonary and Respiratory Medicine
- Biomaterials
- Co-authors
- Jan H.M. SchellensJos H. BeijnenBastiaan NuijenAdam F. CohenR.C.A. SchellekensHenderik W. FrijlinkJos G. W. KosterinkMatthijs D. Kruizinga
- Topics
- Cancer Treatment and Pharmacology (9 papers)Pharmacogenetics and Drug Metabolism (5 papers)Cancer therapeutics and mechanisms (5 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaPLoS ONE
- Partner nations
- NetherlandsUnited StatesFrance
In The Last Decade
Frederik E. Stuurman
40 papers receiving 648 citations
Peers
Comparison fields: 5 of 117
- Oncology 138
- Pharmaceutical Science 115
- Molecular Biology 108
- Pulmonary and Respiratory Medicine 97
- Biomaterials 65
Countries citing papers authored by Frederik E. Stuurman
This map shows the geographic impact of Frederik E. Stuurman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederik E. Stuurman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederik E. Stuurman more than expected).
Fields of papers citing papers by Frederik E. Stuurman
This network shows the impact of papers produced by Frederik E. Stuurman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederik E. Stuurman. The network helps show where Frederik E. Stuurman may publish in the future.
Co-authorship network of co-authors of Frederik E. Stuurman
This figure shows the co-authorship network connecting the top 25 collaborators of Frederik E. Stuurman. A scholar is included among the top collaborators of Frederik E. Stuurman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederik E. Stuurman. Frederik E. Stuurman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 5 | |
| 3 | 3 | |
| 4 | 3 | |
| 5 | 7 | |
| 6 | 18 | |
| 7 | 7 | |
| 8 | 9 | |
| 9 | 34 | |
| 10 | 13 | |
| 11 | 16 | |
| 12 | 4 | |
| 13 | 16 | |
| 14 | 1 | |
| 15 | 22 | |
| 16 | 36 | |
| 17 | 2 | |
| 18 | 29 | |
| 19 | 117 | |
| 20 | 70 |
About Frederik E. Stuurman
Frederik E. Stuurman is a scholar working on Pharmacology, Oncology and Pharmaceutical Science, having authored 40 papers that have together received 662 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), Pharmacogenetics and Drug Metabolism (5 papers) and Cancer therapeutics and mechanisms (5 papers). The work is most often cited by research in Pharmaceutical Science (115 citations), Gastroenterology (35 citations) and Transplantation (15 citations). Frederik E. Stuurman has collaborated with scholars based in Netherlands, United States and France. Frequent co-authors include Jan H.M. Schellens, Jos H. Beijnen, Bastiaan Nuijen, Adam F. Cohen, R.C.A. Schellekens, Henderik W. Frijlink, Jos G. W. Kosterink, Matthijs D. Kruizinga, Jacobus Burggraaf and Frans Stellaard. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.